Obstructive Sleep Apnea (OSA) affects millions worldwide, and until recently, treatment options were limited to lifestyle changes, CPAP therapy, oral appliances, and surgeries. In December 2024, the U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) as the first medication indicated specifically for adults with moderate to severe OSA and obesity. This represents a significant milestone in sleep-related breathing disorder care.
How Does Zepbound Work?
Zepbound is a once-weekly injectable therapy that acts on two hormones (GLP-1 and GIP) involved in appetite regulation, metabolic activity, and weight management. Because obesity is one of the strongest risk factors for OSA, researchers studied whether weight loss from tirzepatide could improve airway stability during sleep.
Key findings from clinical trials:
• Participants experienced clinically meaningful reductions in apnea-hypopnea index (AHI).
• Average weight loss reached 16–20%, depending on dosage.
• Many participants moved into lower OSA severity categories or approached partial remission.
Who May Benefit?
Adults who have:
• Moderate to severe OSA
• Obesity (BMI ≥30)
• Difficulty achieving symptom relief through lifestyle modifications
• Struggles with CPAP adherence
It is important to note that Zepbound is not a substitute for CPAP for all patients. Many individuals will continue to benefit from established therapies.
Safety Considerations
Side effects may include nausea, diarrhoea, abdominal discomfort, and fatigue. Zepbound is not recommended for individuals with certain thyroid conditions or those with a personal or family history of medullary thyroid carcinoma.
Conclusion
Zepbound offers a new medical pathway for eligible adults with OSA and obesity. It should always be prescribed and monitored by a qualified clinician as part of a comprehensive treatment plan.
References
1. FDA. “FDA Approves First Medication for Obstructive Sleep Apnea.”
2. Eli Lilly Trial Data Summary.
3. Peer-reviewed analyses on GLP-1/GIP agonists and OSA outcomes.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Diagnosis and treatment of sleep disorders must be performed by licensed healthcare professionals.
